Avis F, Avis I, Newsome J F, Haughton G
J Natl Cancer Inst. 1976 Jan;56(1):17-25. doi: 10.1093/jnci/56.1.17.
Peripheral lymphocytes obtained from 12 of 13 patients who had fibrocystic disease (FCD) of the breast were specifically cytotoxic to breast adenocarcinoma cells, as measured in vitro by the microcytotoxicity test. Sera from 6 women with active FCD or metastatic breast cancer could specifically block the cytotoxicity of lymphocytes from either population of patients against cancer cells. This implied extensive antigenic cross-reactivity between benign and malignant hyperplastic disease of the breast. Sera from 4 individuals clinically free of FCD or breast fibroadenoma (FAD) neutralized the blocking activity in the sera of patients with metastatic breast cancer. Patients "cured" of FCD or FAD represented a pool of potential plasma donors for immunotherapy of recurrent breast cancer.
通过微细胞毒性试验体外检测发现,13例患有乳腺纤维囊性疾病(FCD)的患者中有12例的外周淋巴细胞对乳腺腺癌细胞具有特异性细胞毒性。6例患有活动性FCD或转移性乳腺癌的女性的血清能够特异性阻断这两组患者的淋巴细胞对癌细胞的细胞毒性。这意味着乳腺良性和恶性增生性疾病之间存在广泛的抗原交叉反应。4例临床上无FCD或乳腺纤维腺瘤(FAD)的个体的血清中和了转移性乳腺癌患者血清中的阻断活性。“治愈”FCD或FAD的患者是复发性乳腺癌免疫治疗潜在血浆供体的来源。